Clinical Trial Update: Study of Pyrotinib in Patients With Human Epidermalgrowth Factor Receptor 2 (HER2) Positive Advanced Breast Cancer [Phase 1]

View source ↗

Summary

This Phase 1 trial update reports on the safety and preliminary activity of Pyrotinib in patients with HER2-positive advanced breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Pyrotinib (pyrotinib)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Breast Cancer | Phase 1 | Status: COMPLETED